Arrowhead Pharmaceuticals, Inc. (ARWR) - 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended March 31, 2026 (Fiscal Q2 2026). Arrowhead Pharmaceuticals is a biopharmaceutical company developing RNA interference (RNAi) therapeutics. The company operates as a single segment. Key approved products include REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (FCS), which received FDA approval in November 2025 and NMPA approval in January 2026. The company maintains a robust pipeline across cardiometabolic, pulmonary, liver, and neuromuscular therapeutic areas.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Mar 31, 2026 | Six Months Ended Mar 31, 2026 | Balance Sheet (Mar 31, 2026) |
|---|---|---|---|
| Revenue | $73,737 | $337,770 | - |
| Net Loss (Attributable to ARWR) | $(132,732) | $(101,919) | - |
| Operating Loss | $(141,260) | $(100,451) | - |
| Net Cash Provided by Operating Activities | - | $97,923 | - |
| Cash, Cash Equivalents & Restricted Cash | - | - | $188,517 |
| Available-for-Sale Securities | - | - | $1,595,574 |
| Total Debt (Credit Facility + Convertible Notes) | - | - | $881,579 |
| Stockholders' Equity | - | - | $613,977 |
Note: Total Debt includes $200,000 in Credit Facility principal (current + long-term) and $700,000 in Convertible Notes principal.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased significantly from $542.7 million in Q2 2025 to $73.7 million in Q2 2026. This was primarily due to the recognition of a large upfront payment from the Sarepta Collaboration Agreement in the prior year, partially offset by new revenue from Novartis ($20.5M) and Sanofi ($10.5M).
- Operating Expenses: Total operating expenses increased to $215.0 million (Q2 2026) from $161.5 million (Q2 2025).
- R&D Expenses: Increased 30% to $173.3 million, driven by higher candidate costs ($99.4M) as the pipeline advanced into clinical trials and expanded manufacturing capabilities.
- SG&A Expenses: Increased 47% to $41.7 million, largely due to commercialization costs for the REDEMPLO launch and increased headcount.
- Profitability: The company reported a net loss of $132.7 million for the quarter, compared to a net income of $370.4 million in the same period last year. The prior year income was heavily influenced by the Sarepta upfront payment.
- Capital Structure: The company significantly strengthened its balance sheet by issuing $700 million in 0.00% Convertible Notes due 2032 and completing a follow-on equity offering generating $230 million in gross proceeds.
Guidance, Outlook, and Risks
- Liquidity: Management expects sufficient liquidity to fund operations for at least the next 12 months. Total liquid resources (cash + investments) exceed $1.7 billion.
- Outlook: The company is transitioning toward commercialization with REDEMPLO. Key upcoming milestones include the expected European Commission decision on REDEMPLO in Q2 2026 and continued progression of the pipeline (e.g., ARO-DIMER-PA, ARO-PNPLA3).
- Recent Agreements:
- Novartis: Received $200M upfront; eligible for up to $2.0B in milestones.
- Sarepta: Received $200M milestone payment in Q2 2026; eligible for further milestones and royalties.
- Madrigal (Subsequent Event): Entered into a licensing agreement for ARO-PNPLA3 with a $25M upfront payment and up to $975M in milestones.
- Risks:
- Patent Litigation: Ongoing dispute with Ionis Pharmaceuticals regarding the '333 patent. The company's declaratory judgment action was dismissed, and Ionis filed an infringement suit.
- Regulatory Approval: Future revenue depends on regulatory approvals for pipeline candidates and REDEMPLO in various jurisdictions.
- Debt Covenants: The Credit Facility requires maintaining liquidity of at least $250 million if market cap exceeds $2.0 billion.
Investor Verification Checklist
- Revenue Recognition Timing: Verify the sustainability of revenue streams given the heavy reliance on upfront milestone payments from Sarepta in the prior year versus the current quarter's lower revenue.
- Debt Service Obligations: Review the terms of the $500M Credit Facility (15% PIK interest, MOIC payments) and the $700M Convertible Notes to understand future cash flow impacts and dilution risks.
- REDEMPLO Commercialization: Assess the actual sales performance and market penetration of REDEMPLO following FDA and NMPA approvals to validate commercialization expense assumptions.
- Patent Litigation Status: Monitor the outcome of the Ionis Pharmaceuticals patent infringement lawsuit, which could impact the commercialization of plozasiran.
- Cash Burn Rate: Analyze the trend in R&D and SG&A expenses to ensure the current cash position supports the aggressive pipeline expansion and commercial launch plans.